Clinical Trials Logo

Filter by:
NCT ID: NCT00417638 Completed - Clinical trials for Acute Anterior Myocardial Infarction

Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to Percutaneous Coronary Intervention

Start date: January 2007
Phase: N/A
Study type: Interventional

Rapid MI-ICE-Pilot is designed to demonstrate the safety and efficacy of the Celsius Controlâ„¢ System (CCS) endovascular catheter to reduce the infarct size resulting from acute anterior myocardial infarction when used in combination with cold saline as an adjunct to immediate percutaneous coronary intervention (PCI) in patients with an occluded infarct-related artery.

NCT ID: NCT00417131 Completed - Diabetes Type 1 Clinical Trials

Imaging of Islet Transplantation With PET and MRT

Start date: October 2006
Phase: N/A
Study type: Observational

Islets of Langerhans intended for clinical transplantation are labelled with a radioactive tracer. The tracer is retained in viable cells of the transplant. At infusion (transplantation) of the islets into the portal vein the tracer can be followed for two hours with positron emission tomography (PET). Imaging and calculations can give estimates of the proportion of surveying islets and the rate of early destruction. Also the distribution of the islets into the liver can be viewed.

NCT ID: NCT00417118 Completed - Generalized Anxiety Clinical Trials

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder. The secondary objectives are to evaluate the efficacy of saredutant on disability and quality of life in patients with generalized anxiety disorder, and to evaluate blood levels of saredutant.

NCT ID: NCT00417079 Completed - Neoplasms Clinical Trials

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

TROPIC
Start date: January 2007
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere®-containing regimen. The primary objective is overall survival. Secondary objectives include progression free survival, overall response rate, prostate-specific antigen (PSA) response/progression, pain response/progression, overall safety, and pharmacokinetics. Patients will be treated until disease progression, death, unacceptable toxicity, or for a maximum of 10 cycles. Patients will have long-term follow-up for a maximum of up to 2 years.

NCT ID: NCT00415363 Completed - Clinical trials for Non Small Cell Lung Cancer

Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer. Approximately 108 patients will be randomly assigned to receive either enzastaurin or placebo after having completed whole brain radiotherapy.

NCT ID: NCT00415181 Completed - Ovarian Neoplasms Clinical Trials

Pharmacogenomics of Paclitaxel in Ovarian Cancer

Start date: September 2006
Phase: N/A
Study type: Observational

This study will try to determine whether or not certain genes are responsible for the huge variation in toxicity and effect observed between patients treated with paclitaxel (chemotherapeutic drug). Specifically we will study this in patients with ovarian cancer who receive paclitaxel/carboplatin chemotherapy after primary surgery.

NCT ID: NCT00415142 Completed - Depressive Disorder Clinical Trials

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy of saredutant in the treatment of Major Depressive Disorder in elderly patients.To evaluate the tolerability, safety and efficacy on disability and quality of life in patients with major depressive disorder.To evaluate plasma concentrations of saredutant and SR49596 (inactive metabolite).To evaluate safety and tolerability of 24 weeks of additional treatment in patients completing the initial 8-week treatment period.

NCT ID: NCT00414609 Completed - Clinical trials for Myocardial Infarction

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).

NCT ID: NCT00413699 Completed - Clinical trials for Arthritis, Rheumatoid

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Start date: February 5, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550

NCT ID: NCT00413660 Completed - Clinical trials for Arthritis, Rheumatoid

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.